Baseline characteristics of dropouts (before or at 3 years of follow up) versus completers
| Patient characteristics | UA-RA group | RA-RA group | ||||
|---|---|---|---|---|---|---|
| Dropouts (n = 19) | Completers (n = 72) | p Value | Dropouts (n = 10) | Completers (n = 52) | p Value | |
| Results are shown as number or median (interquartile range). | ||||||
| Age (years) | 64 (46–75) | 55 (44–63) | 0.099 | 57 (36–85) | 53 (46–69) | 0.745 |
| Female patients | 57 | 65 | 0.598 | 60 | 71 | 0.479 |
| Duration of symptoms at first visit (days) | 102 (61–209) | 144 (78–250) | 0.381 | 159 (63–275) | 126 (59–290) | 0.851 |
| Duration of morning stiffness (min) | 60 (30–180) | 60 (15–120) | 0.341 | 75 (41–135) | 90 (45–180) | 0.875 |
| Number of swollen joints | 5 (3–8) | 4 (2–5) | 0.087 | 7 (4–8) | 7 (5–8) | 0.658 |
| Modified DAS score | 3.3 (2.8–4.2) | 3.1 (2.6–3.6) | 0.218 | 3.5 (2.9–4.7) | 3.5 (3.1–4.0) | 0.626 |
| RF positive | 26 | 47 | 0.127 | 60 | 73 | 0.457 |
| Anti-CCP antibodies | 42 | 55 | 0.435 | 50 | 61 | 0.725 |
| ESR (mm/1st h) | 37 (25–65) | 30 (18–50) | 0.091 | 46 (25–61) | 35 (19–57) | 0.410 |
| CRP (mg/l) | 57 (13–74) | 11 (7–32) | 0.002 | 19 (9–44) | 27 (9–42) | 0.984 |
| HAQ score | 1.0 (0.12–1.37) | 0.75 (0.5–1.12) | 0.852 | 1.31 (0.65–1.75) | 1.0 (0.5–1.37) | 0.382 |
| Erosive disease (hands and feet radiographs) | 33 | 29 | 0.695 | 44 | 28 | 0.309 |